Navigation Links
Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2011.  For the three months ended March 31, 2011, Orexigen reported a net loss of $11.6 million, or $0.24 per share, as compared to a net loss of $14.1 million, or $0.30 per share, for the first quarter of 2010.  As of March 31, 2011, Orexigen had $39.6 million in cash and cash equivalents and an additional $36.9 million in marketable securities, for a total of approximately $76.6 million.

"Over the last several months, together with our partner, Takeda, and our external advisors, we have been preparing for a meeting with FDA to discuss a viable path forward for Contrave®," said Michael Narachi, president and CEO of Orexigen. "We have submitted to the Agency a specific, innovative, and robust proposal to assess cardiovascular risk and have confirmed a meeting with the Agency later this quarter to discuss our proposal."

Total operating expenses for the first quarter of 2011 were $13.3 million compared to $14.0 million for the first quarter of 2010. This decrease in operating expenses primarily reflects a decrease in research and development expenses of $1.4 million principally related to the reduction in costs incurred in connection with the preparation for our NDA filing for Contrave in the first quarter of 2011 as compared to same period in 2010. This overall decrease was partially offset by an increase in general and administrative expenses principally related to one-time corporate realignment costs.

Conference Call Today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the first quarter 2011 financial results and recent business highlights. The l
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
2. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
3. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
6. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
7. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
10. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
11. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s increasingly global marketplace ... to reflect the needs of a global marketplace ... the needs of key stakeholders while recognizing regional ... According to recent research by benchmarking firm, Best ... companies averaged more than $100,000 in annual spending ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... FORT WORTH, Texas , December 18, 2014 ... is a networked software application/module that is used ... and related images. RIS comprises a patient tracking ... tracking system. The integration of RIS with HIS ... is used for patient registration and patient scheduling, ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3
... reduce the use of mechanical ventilation with premature infants in ... affect those children,s outcomes while reducing the cost of care, ... The team, led by Bernadette Levesque, MD, ... and the Neonatal Intensive Care Unit (NICU) at St. Elizabeth,s ...
... SPRING, Md., June 10, 2011 The U.S. Food ... Merck,s redesigned drug container labels that include a new ... on product and strength differentiation. (Logo: ... the revision of 34 container labels for 16 solid ...
Cached Medicine Technology:Guidelines for Ventilator Use Help Premature Infants Breathe Easier 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 3FDA Approves Redesigned Labels for Some Merck Drugs 2
(Date:12/19/2014)... December 20, 2014 Today, Balfleet.com ... special-occasion outfits, announces its formal dress promotion. All the ... up to 60% off. , Balfleet.com is well-known for ... bridesmaid dresses, prom dresses, cocktail dresses and more. Its ... 30-day money-back guarantee, and they can create an elegant ...
(Date:12/19/2014)... Energy Textiles is excited to ... Celliant, the world’s leading responsive textile, can now ... There are a number of benefits to wearing ... and balanced body temperature; which can lead to ... enhanced athletic performance; and overall wellness. In addition, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Potentially illness-causing ... herbs bought at farmers markets, according to a new ... almost 50 vendors from 13 farmers markets in Los ... Seattle area. Out of almost 150 samples tested, 24 ... positive for salmonella, according to the researchers. Both ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... ... best hospitals in the United States by U.S. News & World Report. , ... New York, NY (Vocus) July 16, 2009 -- The Mount Sinai Medical ... States by U.S. News & World Report. , , ,In the 2009-10 America,s Best Hospital issue, Mount ...
... , BOCA RATON, Fla., July 16 JAG ... further update of the status of its acquisition of CardioGenics ... closing date for the acquisition, currently scheduled for a date ... a date on or before July 24, 2009 to allow ...
... ... their practices and prepare for the future just launched on Monday. , ... (Vocus) July 16, 2009 -- The ... 25 years of combined experience in dental practice sales and appraisals, is the first membership-based, ...
... , , WASHINGTON, July 16 ... committees crafting the House version of a health care reform bill ... those revenues to a special fund to finance prevention and wellness ... taxes are an important tool in reducing the public health toll ...
... to higher risk of heart attack, stroke, agency says, ... Food and Drug Administration has begun a safety review ... an increased risk of heart attack, abnormal heart rhythm, ... Early results from the Evaluating the Clinical Effectiveness and ...
... , , , BEDFORD, Ohio, ... Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. ... by Roche. Ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO ...
Cached Medicine News:Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 2Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 3Health News:JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc. 2Health News:National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 2Health News:Raise Federal Alcohol Tax to Finance Prevention Trust Fund, Partnership Urges House Chairmen 2Health News:FDA Investigating Safety of Asthma Drug Xolair 2Health News:Bedford Laboratories(TM) to Begin Shipping Ceftriaxone for Injection USP 2
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
STABIBAG Hydrophilic Acrylic Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
One piece multifocal acrylic intraocular lens....
Medicine Products: